While cardiovascular outcome trials are critical to demonstrating clinical value, they can also be complex and costly. Among the most challenging aspects are the people involved, from patients to investigators and commit...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Mitigating the impact of COVID-19 on CV trials and participants
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19 by adopting patient-centric technologies to keep patients safe and studies on track. The article is published in PharmaFile Spring 2020 on page 40.
-
Here’s what we have to do to show a coronavirus vaccine works
A article featuring expert commentary from ICON's Cynthia Dukes about the development of a vaccine for COVID-19.
-
Improving access and reimbursement for specialty therapies
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, payers are scrutinising the economic value more closely. ICON experts discuss how clinical development can better satisfy the evidence needs of HTA bodies and payers.
-
Women in healthcare: Dr. Nuala Murphy
Pharma Times interviews Dr. Nuala Murphy, ICON's President of Clinical Research Services.
-
Ex-AstraZeneca exec Kristen Buck hops aboard ICON as CMO
Dr. Kristen Buck joins ICON as its new chief medical officer.
-
While the world waits
ICON's Cindy Dukes considers the best practices for developing a vaccine and treatments for COVID-19.
-
ICON nabs former Optum, FDA and AstraZeneca exec as new chief medical officer
Fierce Biotech reports on ICON's appointment of Dr. Kristen Buck as its new chief medical officer.
-
Company of the Month April 2020: ICON plc’s Q1 figures indicate strong growth
Business & Finance names ICON as 'Company of the Month' for April 2020.
-
The U.S. biosimilars market: Shaking the “laggard” label
An article by Katya Svoboda and Bob Swann which explores the fundamental differences in the regulatory processes and the market dynamics of the US and the EU which account for much of the discrepancy in the uptake of biosimilars.
-
Thwarting Cyber attacks: Steps to implement security into mHealth development
A thought leadership piece authored by David Novotny, Marie McCarthy and Tony Clarke which considers the potential risks of cyber threats in mHealth. See pages 18-19 of the May 2020 edition of PharmaFocus magazine.
